The Incyte Corporation (INCY) Shares Sold by Endurant Capital Management LP

The Incyte Corporation (INCY) Shares Sold by Endurant Capital Management LP

Endurant Capital Management LP decreased its stake in Incyte Corporation (NASDAQ:INCY) by 39.8% during the third quarter, Holdings Channel reports. The firm owned 5,000 shares of the biopharmaceutical company’s stock after selling 3,300 shares during the period. Endurant Capital Management LP’s holdings in Incyte Corporation were worth $471,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Matrix Capital Management Company LP purchased a new stake in shares of Incyte Corporation during the third quarter valued at approximately $132,006,000. Pictet Asset Management Ltd. raised its stake in shares of Incyte Corporation by 241.5% in the second quarter. Pictet Asset Management Ltd. now owns 760,513 shares of the biopharmaceutical company’s stock valued at $64,195,000 after buying an additional 537,800 shares during the period. Capital International Investors raised its stake in shares of Incyte Corporation by 9.2% in the second quarter. Capital International Investors now owns 5,918,033 shares of the biopharmaceutical company’s stock valued at $473,324,000 after buying an additional 499,536 shares during the period. Marshall Wace LLP raised its stake in shares of Incyte Corporation by 224.0% in the second quarter. Marshall Wace LLP now owns 637,663 shares of the biopharmaceutical company’s stock valued at $51,000,000 after buying an additional 440,877 shares during the period. Finally, Frontier Capital Management Co. LLC raised its stake in shares of Incyte Corporation by 64.7% in the second quarter. Frontier Capital Management Co. LLC now owns 810,408 shares of the biopharmaceutical company’s stock valued at $64,816,000 after buying an additional 318,495 shares during the period. 91.91% of the stock is currently owned by institutional investors and hedge funds.

Incyte Corporation (NASDAQ:INCY) traded down 2.87% during trading on Monday, reaching $118.23. 1,346,146 shares of the company’s stock were exchanged. The company’s 50-day moving average is $109.48 and its 200-day moving average is $94.74. Incyte Corporation has a 1-year low of $55.00 and a 1-year high of $122.68. The company has a market capitalization of $22.27 billion, a PE ratio of 158.91 and a beta of 0.83.

INCY has been the topic of a number of recent research reports. Goldman Sachs Group, Inc. (The) upped their target price on Incyte Corporation from $116.00 to $149.00 and gave the company a “buy” rating in a research note on Friday. JMP Securities reaffirmed an “outperform” rating and issued a $130.00 target price on shares of Incyte Corporation in a research note on Wednesday, January 18th. Zacks Investment Research raised Incyte Corporation from a “hold” rating to a “buy” rating and set a $107.00 target price on the stock in a research note on Tuesday, October 4th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $126.00 target price (up previously from $121.00) on shares of Incyte Corporation in a research note on Saturday, November 19th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $98.00 target price on shares of Incyte Corporation in a research note on Wednesday, October 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $109.93.

In other Incyte Corporation news, EVP Reid M. Huber sold 2,715 shares of Incyte Corporation stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $109.95, for a total transaction of $298,514.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 13.70% of the company’s stock.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).

Related posts

Leave a Comment